Therapeutic preparation of very high purity FVIIa and method for obtaining same

a technology of very high purity and preparation method, which is applied in the field of very high purity fviia preparation and the preparation of the same, can solve the problems of reducing the efficacy of this treatment, limited purification degree, industrial complex and expensive method

Active Publication Date: 2009-05-12
GRIFOLS
View PDF10 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025]The eluate, rich in FVII, is applied to a metal chelation column, with a Ni Sepharose HP resin, adsorbing the FVII at a pH between 7.5 and 8.5. This resin makes it possible to carry out washings in high conductivity conditions and also at a pH between 6 and 7. The elution of FVII with a solution which contains 10 mmol / l anhydrous disodium phosphate, 25 mmol / l NaCl, adjusted to neutral pH makes it possible to obtain a high purity FVII, with a specific activity of around 200 IU / mg of protein.

Problems solved by technology

Unfortunately, one of the problems of therapy with FVIII is the appearance of FVIII-inhibiting antibodies, which reduces the efficacy of this treatment.
As has been observed, in the purification processes based on precipitation, the degree of purification obtained is limited, describing moreover complex processes in which the separation of precipitates is by centrifuging, which is an industrially complex and expensive method.
By the method described, it is not possible to obtain a high purity FVIIa.
With this method a high purity is obtained (specific activity of the order of 40,000 IU / mg of protein), but it is not possible to dismiss the presence, in the final product, of proteins of non-human origin coming from the monoclonal antibodies released by the resin used.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example

[0028]Attached below by way of illustration is an exemplary embodiment of the present invention, divided into the consecutive stages 1 to 4.

Stage 1

[0029]Obtaining an impure fraction of FVII on precipitating the extraction of the fraction of II+III:

[0030]The initial suspension of the fraction II+III was carried out with an extraction solution of 5 mmol / l phosphate and 5% sorbitol.

[0031]Once the suspension was completed, it was maintained for 1 hour at 2-6° C. while agitating. After adjustment of the pH, PEG was added to the suspension of the fraction II+III to a final concentration of 4% (w / w). After the addition, the suspension was agitated for 30 minutes. To the previously obtained suspension, bentonite was added, agitating it afterwards for 20 minutes, from which time a rest stage of at least 4 hours commenced. After this the centrifuging process commenced for 20 minutes. Once the centrifuging process was completed, the supernatant was separated from the precipitate. The latter wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The therapeutic preparation of FVIIa having a purity of at least 1000 IU / mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to Spanish patent application Ser. No. 200600373 filed Feb. 17, 2006, the contents of which are hereby incorporated by reference in their entirety.DESCRIPTION[0002]The present invention relates to a therapeutic preparation of very high purity FVIIa and a method for obtaining same, which have notable characteristics of novelty and inventive step.BACKGROUND[0003]The treatment of haemorrhagic problems in haemophilia and other related disorders, such as liver disease, is carried out by means of substitution therapy with clotting factors.[0004]The treatment of choice in haemophilia A (deficiency of clotting factor VIII) comprises the administration of said factor VIII (FVIII), both at the prophylactic level and in acute episodes. Unfortunately, one of the problems of therapy with FVIII is the appearance of FVIII-inhibiting antibodies, which reduces the efficacy of this treatment.[0005]Other alternative treatmen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/36C07K14/745
CPCA61K38/36A61P7/02A61P7/04
Inventor GRANCHA GAMON, SALVADORRISTOL DEBART, PEREJORQUERA NIETO, JUAN IGNACIO
Owner GRIFOLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap